

REPROS THERAPEUTICS INC.

Form 8-K

June 06, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

Current Report Filed Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report
(Date of earliest event reported): June 1, 2011

Repros Therapeutics Inc.
(Exact name of registrant as specified in its charter)

Delaware	001-15281	76-0233274
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)
	2408 Timberloch Place, Suite B-7	
	The Woodlands, Texas 77380	
	(Address of principal executive offices and zip code)	
	(281) 719-3400	
	(Registrant's telephone number, including area code)	

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 1, 2011, the Compensation Committee (the "Committee") of the Board of Directors of Repros Therapeutics Inc. (the "Company") approved the grant of an option to purchase 100,000 shares of the Company's common stock to Joseph S. Podolski, President and Chief Executive Officer of the Company. The stock option was granted pursuant to the Company's 2011 Equity Incentive Plan (the "Plan") and has an exercise price equal to \$5.64 per share, the closing price per share of the Company's common stock on the date of grant. The option vests based upon achievement of various clinical development and corporate milestones established by the Committee to be accomplished prior to June 30, 2012.

A copy of the Plan is filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 4, 2011.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Repros Therapeutics Inc.

Date: June 6, 2011

By: /s/ Katherine A. Anderson
Katherine A. Anderson
Chief Accounting Officer
